Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

被引：0
|
作者：
Morschhauser, Franck [1 ]
Bishton, Mark [2 ]
Eyre, Toby A. [3 ]
Bachy, Emmanuel [4 ]
Cartron, Guillaume [5 ]
Ysebaert, Loic [6 ]
Bobillo, Sabela [7 ]
Gutierrez, Norma C. [8 ]
Budde, Elizabeth [9 ]
Fox, Christopher P. [2 ]
Knapp, Andrea [10 ]
Yaqub, Manejeh [11 ]
Wei, Michael C. [11 ]
O'Hear, Carol [11 ]
Li, Haocheng [12 ]
Purev, Enkhtsetseg [11 ]
Townsend, William [13 ]
机构：
[1] Univ Lille, Grp Res Formes Injectables & Technol Associees, Lille, France
[2] Nottingham Univ Hosp NHS Trust, Nottingham, England
[3] Oxford Univ Hosp NHS Trust, Oxford, England
[4] Ctr Hosp Lyon Sud, Lyon, France
[5] CHU Montpellier, Montpellier, France
[6] CHU Toulouse, Toulouse, France
[7] Hosp Univ Valle de Hebron, Barcelona, Spain
[8] Hosp Univ Salamanca, Salamanca, Spain
[9] City Hope Natl Med Ctr, Duarte, CA USA
[10] F Hoffmann La Roche Ltd, Basel, Switzerland
[11] Genentech Inc, San Francisco, CA USA
[12] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[13] Univ Coll London Hosp BRC Clin Res Facil, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH22-PO58
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [1] Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study
    Morschhauser, Franck
    Bishton, Mark
    Eyre, Toby A.
    Bachy, Emmanuel
    Cartron, Guillaume
    Ysebaert, Loic
    Bobillo, Sabela
    Gutierrez, Norma C.
    Budde, L. Elizabeth
    Fox, Christopher P.
    Knapp, Andrea
    Yaqub, Manejeh
    Wei, Michael C.
    O'Hear, Carol
    Li, Haocheng
    Purev, Enkhtsetseg
    Townsend, William
    BLOOD, 2021, 138
  • [2] Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study
    Wang, Michael L.
    Assouline, Sarit
    Kamdar, Manali
    Ghosh, Nilanjan
    Naik, Seema
    Nakhoda, Shazia K.
    Chavez, Julio C.
    Jia, Ting
    Pham, Song
    Huw, Ling-Yuh
    Jing, Jing
    Ead, Wahib
    To, Iris
    Batlevi, Connie Lee
    Wei, Michael C.
    Budde, L. Elizabeth
    BLOOD, 2023, 142
  • [3] Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study
    Flinn, Ian W.
    Budde, L. Elizabeth
    Tun, Aung M.
    Burke, John M.
    Anz, Bertrand
    Peles, Shachar
    Sharman, Jeff P.
    Tumula, Praveen K.
    Biondo, Juliana M. L.
    Jani, Prachi
    Wu, Mei
    Lin, Tony
    Parmar, Neha
    Mun, Yong
    Yao, Nai-Shun
    Liu, Steven
    BLOOD, 2023, 142
  • [4] Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial
    Salles, Gilles
    Ghosh, Nilanjan
    Lossos, Izidore S.
    Palomba, Maria Lia
    Mehta, Amitkumar
    Casasnovas, Olivier
    Stevens, Don
    Abajo, Ana
    Nielsen, Tina
    Chitra, Surya
    Wenger, Michael
    Morschhauser, Franck
    BLOOD, 2018, 132
  • [5] Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/ refractory follicular lymphoma who received ≥2 prior therapies: updated results from a pivotal Phase II study
    Dietrich, S.
    Bartlett, N. L.
    Sehn, L. H.
    Matasar, M.
    Schuster, S. J.
    Assouline, S.
    Giri, P.
    Kuruvilla, J.
    Canales, M.
    Fay, K.
    Ku, M.
    Nastoupil, L.
    Wie, M. C.
    Yin, S.
    To, I.
    Huang, H.
    Min, J.
    Bolen, C. R.
    Penuel, E.
    Budde, L. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 211 - 212
  • [6] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/ Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
    Bartlett, Nancy L.
    Sehn, Laurie H.
    Matasar, Matthew J.
    Schuster, Stephen J.
    Assouline, Sarit E.
    Giri, Pratyush
    Kuruvilla, John
    Canales, Miguel
    Dietrich, Sascha
    Fay, Keith
    Ku, Matthew
    Nastoupil, Loretta
    Wei, Michael C.
    Yin Shen
    To, Iris
    Huang Huang
    Min, Juliana
    Bolen, Christopher R.
    Penuel, Eliciaand
    Elizabeth, Budde L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S44 - S44
  • [7] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
    Bartlett, Nancy L.
    Sehn, Laurie H.
    Matasar, Matthew J.
    Schuster, Stephen J.
    Assouline, Sarit
    Giri, Pratyush
    Kuruvilla, John
    Canales, Miguel
    Dietrich, Sascha
    Fay, Keith
    Ku, Matthew
    Nastoupil, Loretta J.
    Wei, Michael C.
    Yin, Shen
    To, Iris
    Huang, Huang
    Min, Juliana
    Penuel, Elicia
    Budde, L. Elizabeth
    BLOOD, 2022, 140 : 1467 - 1470
  • [8] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study
    Bartlett, Nancy L.
    Sehn, Laurie H.
    Matasar, Matthew
    Schuster, Stephen J.
    Assouline, Sarit
    Giri, Pratyush
    Kuruvilla, John
    Canales, Miguel
    Dietrich, Sascha
    Fay, Keith
    Ku, Matthew
    Nastoupil, Loretta
    Wei, Michael C.
    Yin, Shen
    To, Iris
    Huang, Huang
    Min, Juliana
    Bolen, Christopher R.
    Penuel, Elicia
    Budde, L. Elizabeth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S453 - S453
  • [9] Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation
    Cheah, Chan Y.
    Assouline, Sarit
    Baker, Ross
    Bartlett, Nancy L.
    El-Sharkawi, Dima
    Giri, Pratyush
    Ku, Matthew
    Schuster, Stephen J.
    Matasar, Matthew
    Radford, John
    Wei, Michael C.
    Yin, Shen
    To, Iris
    Huang, Jiangeng
    Kwan, Antonia
    Budde, L. Elizabeth
    BLOOD, 2023, 142
  • [10] Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide
    Bishton, Mark
    Woestmann, Corinna
    Morschhauser, Franck
    Eyre, Toby A.
    Shin, Maria
    Schroeder, Aaron
    Belousov, Anton
    Li, Haocheng
    Knapp, Andrea
    Wei, Michael C.
    Purev, Enkhtsetseg
    Bottos, Alessia
    BLOOD, 2022, 140 : 3555 - 3556
12345